JointHealth™ express November 14, 2022
Let BC PharmaCare hear "Your Voice" on belimumab (Benlysta™) for the treatment of lupus nephritis
You can give input if you are a B.C. resident and have lupus nephritis, a caregiver to someone with lupus nephritis, or if your group represents people who live with lupus nephritis.
If you would like our help in providing your input, you can email your comments to feedback@jointhealth.org or call us at 604-974-1366. Your feedback will be anonymized and collated with others who choose to provide it to ACE for submission on their behalf. Please provide your input to us by Friday, November 18 so that we may submit the questionnaire in time for the deadline.
The submission deadline is November 22, 2022. Patients and caregivers may give their input directly through the link below.
Please click on information sheet link below to learn more about belimumab and the questionnaire link below to let BC PharmaCare hear Your Voice:
Let BC PharmaCare hear "Your Voice" on belimumab (Benlysta™) for the treatment of lupus nephritis
 | Belimumab (Benlysta™) is now being considered for coverage under the British Columbia Ministry of Health’s PharmaCare program. By filling out a questionnaire on a website called Your Voice, you can provide feedback about belimumab for the treatment of lupus nephritis. |
You can give input if you are a B.C. resident and have lupus nephritis, a caregiver to someone with lupus nephritis, or if your group represents people who live with lupus nephritis.
If you would like our help in providing your input, you can email your comments to feedback@jointhealth.org or call us at 604-974-1366. Your feedback will be anonymized and collated with others who choose to provide it to ACE for submission on their behalf. Please provide your input to us by Friday, November 18 so that we may submit the questionnaire in time for the deadline.
The submission deadline is November 22, 2022. Patients and caregivers may give their input directly through the link below.
Please click on information sheet link below to learn more about belimumab and the questionnaire link below to let BC PharmaCare hear Your Voice:
- To view the information sheet for belimumab for the treatment of lupus nephritis: click here
- To complete the Questionnaire as a patient, caregiver, or patient group representative: click here
Arthritis Consumer Experts
ACE thanks Arthritis Research Canada (ARC) for its scientific review of ACE and JointHealth™ information and education programs.